)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Selvita S.A.
Selvita S.A. (SLV) investor relations material
Selvita S.A. Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary18 Sep, 2026
Executive summary
Revenues from sales in H1 2026 were PLN 158.1 million, down 14% year-over-year, mainly due to a sharp decline in biotech client demand and price competition from Asian providers.
Net loss for H1 2026 was PLN 8.5 million, compared to a net loss of PLN 5.6 million in H1 2025, reflecting lower operating profitability.
EBITDA (excluding incentive scheme) was PLN 23.9 million, down 23% year-over-year, mainly due to weaker Drug Discovery performance.
The Group maintained liquidity and fulfilled obligations, with cash at PLN 16.6 million as of June 30, 2026.
Financial highlights
Total assets at June 30, 2026: PLN 582.8 million, down from PLN 597.8 million at December 31, 2025.
Equity decreased to PLN 315.5 million, mainly due to the net loss.
Current ratio declined to 1.03 from 1.17 at year-end 2025; quick ratio at 0.96.
Net cash flows from operating activities were PLN 2.2 million, a significant drop from PLN 22.3 million in H1 2025.
No dividends declared or paid in the period.
Outlook and guidance
Backlog as of September 15, 2026 was PLN 305.7 million, down 8.5% year-over-year, with Drug Discovery backlog down 23% and Drug Development backlog up 23%.
Management expects continued pressure on Drug Discovery due to selective funding and competition, but cost optimization measures are expected to yield further savings.
Key factors for future results include sales dynamics, biotech funding access, resource utilization, pricing pressure, and currency fluctuations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Selvita S.A.
- Adjusted EBITDA rose 19%, but reported results included a PLN 52.6m Ardigen gain.SLV
Q4 2023 - Revenue down 12% and net loss posted, but 2025 backlog up 32% after PozLab acquisition.SLVQ2 2024
- Q1 2025 delivered strong revenue and EBITDA growth, with stable backlog and solid liquidity.SLVQ1 2025
- Q1 2026 revenue fell 11% but strong backlog, liquidity, and new contracts support outlook.SLVQ1 2026
- Strong 2025 growth and cost savings set a cautious but positive tone for 2026.SLVQ4 2025
- Revenue and EBITDA grew, with cost savings and backlog supporting future outlook.SLVQ3 2025
- H1 2025 saw 18% revenue growth, higher EBITDA, and cost-saving measures amid market recovery.SLVQ2 2025
- Revenue down, net loss posted, but Drug Development and 2025 backlog show strong growth.SLVQ3 2024
- Revenue down 1% YoY to PLN 342.2m; 2025 backlog up 11%; PozLab acquired; audit unqualified.SLVQ4 2024
Next Selvita S.A. earnings date
Q3 202619 Nov, 2026
Selvita S.A.
Next Selvita S.A. earnings date
Q3 202619 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Selvita S.A. is active in the pharmaceutical and biotechnology sectors. The company specializes in providing integrated services that encompass a wide range of solutions to support drug discovery, regulatory studies, and research and development. Selvita offers comprehensive drug discovery support from the initial stages of target validation through to the preclinical research phase, including the development and validation of drug testing and bioanalytical methods. The organization works closely with various research institutes and universities primarily in Europe and the United States. Founded in 2007, Selvita employs a large team of professionals, including a significant proportion with PhD qualifications. The company is headquartered in Krakow, Poland, and its shares are listed on the Warsaw Stock Exchange.